Molecular Regulation of cardiac adrenergic signaling
心脏肾上腺素信号传导的分子调节
基本信息
- 批准号:10425249
- 负责人:
- 金额:$ 43.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:A kinase anchoring proteinAdrenergic AgentsAdrenergic ReceptorAgonistApoptosisArrhythmiaAttenuatedBindingC-terminalCalciumCardiacCardiac MyocytesCardiotoxicityChronicComplexCouplingCyclic AMPCyclic AMP-Dependent Protein KinasesDLG1 geneDataDevelopmentDiseaseDissociationEnsureExposure toFunctional disorderGRK5 geneGTP-Binding ProteinsHeartHeart ContractilitiesHeart failureHypertrophyIsoproterenolL-Type Calcium ChannelsLinkModelingMolecularMusMuscle CellsOrphanPerfusionPeriodicityPharmacologyPhosphorylationPhosphotransferasesPhysiologicalPhysiologyPlayProductionRegulationRoleSarcoplasmic ReticulumScaffolding ProteinSerineSignal TransductionStressTestingTransgenesTransgenic MiceTransgenic OrganismsTreatment Failurebeta-adrenergic receptorbiological adaptation to stresscalmodulin-dependent protein kinase IIconstrictioncytotoxicitygenetic predictorsheart functioninsightmouse modelmutantnovelphosphoric diester hydrolasepreservationpressurereceptorresponsescaffoldtherapeutic targettool
项目摘要
Summary
β adrenergic receptors (βARs) are critical for cardiac function and are linked to HF. Chronic β1AR-cAMP
signaling promotes activation of CaMKII, which is requisite for all the detrimental effects during maladaptive
remodeling in heart. However, the mechanism governing this specific signaling regulation by β1AR in HF
development is still incompletely understood. We aim to reveal a novel supercomplex of cardiac beta1
adrenergic receptor that is orchestrated by scaffold protein SAP97 and connects to L-type calcium channel
directly. Moreover, SAP97 also scaffold AKAP79/PKA and PDE4D8 in the complex to ensure rapid and
robust regulation of L-type calcium channel in local vicinity, which is essential to maintain rhythmic beat-to-
to-beat cardiac contraction during stress response. We aim to gain insight of regulation of this sophisticated
beta1 adrenergic receptor supercomplex in spatially differentiated cardiac myocytes and explore the
dissemble and dysfunction of this complex in disease development via promoting cytotoxicity in heart. We
hypothesize that GRK5 acts as a molecular switch to turn on Epac-dependent activation of CaMKII. We
have generated mice to simulate dissociation of the b1AR-SAP97 complex and to study SAP97-dependent
b1AR signaling in physiology and diseases. This study will provide new insight governing the specific b1AR
signaling involved in physiology an in HF, and offer GRK5 as a complementary therapeutic target for HF.
The hypothesis will be examined in the following aims: Aim 1. A SAP97 complex facilitates PKA-dependent
regulation of EC coupling. Aim 2. Disruption of b1AR-SAP97 interaction promotes b1AR-induced CaMKII
activity. Aim 3. GRK5 phosphorylation of b1AR at S475 controls the binding of b1AR to SAP97 to gate
cardiotoxic CaMKII in HF.
总结
β肾上腺素能受体(β AR)对心脏功能至关重要,并与HF相关。慢性β1AR-cAMP
信号传导促进CaMKII的激活,这是适应不良期间所有有害作用所必需的。
心脏重塑然而,β 1 AR在HF中的这种特异性信号调节机制,
发展仍然不完全清楚。我们的目标是揭示一种新的心脏β 1超复合物
由支架蛋白SAP 97协调并连接到L型钙通道的肾上腺素能受体
直接.此外,SAP 97还在复合物中支架化AKAP 79/PKA和PDE 4D 8,以确保快速和有效地结合。
在局部附近的L型钙通道的强大调节,这是维持节律性搏动所必需的,
在应激反应中的心脏收缩。我们的目标是深入了解这种复杂的监管
β 1肾上腺素能受体超复合物在空间分化的心肌细胞,并探讨
通过促进心脏的细胞毒性,这种复合物在疾病发展中的分解和功能障碍。我们
假设GRK 5作为分子开关开启Epac依赖的CaMK II激活。我们
已经产生了小鼠来模拟b1 AR-SAP 97复合物的解离,并研究SAP 97依赖性
b1 AR信号在生理学和疾病中的作用。这项研究将提供新的见解,管理特定的b1 AR
参与生理学和HF中的信号传导,并提供GRK 5作为HF的补充治疗靶点。
该假设将在以下目标中进行检验:目标1。SAP 97复合物促进PKA依赖性
调节EC偶联。目标2.破坏b1 AR-SAP 97相互作用促进b1 AR诱导的CaMKII
活动目标3。GRK 5在S475处磷酸化b1 AR控制b1 AR与SAP 97的结合,以门控
心脏毒性CaMKII。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Probing spatiotemporal PKA activity at the ryanodine receptor and SERCA2a nanodomains in cardomyocytes.
- DOI:10.1186/s12964-022-00947-8
- 发表时间:2022-09-14
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YANG K XIANG其他文献
YANG K XIANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YANG K XIANG', 18)}}的其他基金
Phosphodiesterases govern nuclear cAMP signaling for gene expression
磷酸二酯酶控制基因表达的核 cAMP 信号传导
- 批准号:
10717183 - 财政年份:2023
- 资助金额:
$ 43.54万 - 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
- 批准号:
10369578 - 财政年份:2021
- 资助金额:
$ 43.54万 - 项目类别:
Desensitization of beta1 adrenergic receptor-nitric oxide signaling in cardiac diseases
心脏病中β1肾上腺素受体-一氧化氮信号的脱敏
- 批准号:
10367949 - 财政年份:2021
- 资助金额:
$ 43.54万 - 项目类别:
Desensitization of beta1 adrenergic receptor-nitric oxide signaling in cardiac diseases
心脏病中β1肾上腺素受体-一氧化氮信号的脱敏
- 批准号:
10618826 - 财政年份:2021
- 资助金额:
$ 43.54万 - 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
- 批准号:
10513328 - 财政年份:2021
- 资助金额:
$ 43.54万 - 项目类别:
Molecular Regulation of cardiac adrenergic signaling
心脏肾上腺素信号传导的分子调节
- 批准号:
9922716 - 财政年份:2019
- 资助金额:
$ 43.54万 - 项目类别:
Molecular Regulation of cardiac adrenergic signaling
心脏肾上腺素信号传导的分子调节
- 批准号:
10155584 - 财政年份:2019
- 资助金额:
$ 43.54万 - 项目类别:
Novel mechanism on subpopulation-dependent biased GPCR signaling in neurons
神经元亚群依赖性偏向 GPCR 信号传导的新机制
- 批准号:
10174956 - 财政年份:2018
- 资助金额:
$ 43.54万 - 项目类别:
Novel mechanism on subpopulation-dependent biased GPCR signaling in neurons
神经元亚群依赖性偏向 GPCR 信号传导的新机制
- 批准号:
9929881 - 财政年份:2018
- 资助金额:
$ 43.54万 - 项目类别:
Novel mechanism on subpopulation-dependent biased GPCR signaling in neurons
神经元亚群依赖性偏向 GPCR 信号传导的新机制
- 批准号:
10372289 - 财政年份:2018
- 资助金额:
$ 43.54万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 43.54万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 43.54万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 43.54万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 43.54万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 43.54万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 43.54万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 43.54万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 43.54万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 43.54万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 43.54万 - 项目类别: